Eli Lilly’s New GLP‑1 Pill Has One Big Advantage

Foundayo can be taken anytime: no injections, no fasting window, and no strict dosing routine.

BY LEILA SHERIDAN, NEWS WRITER

A new weight loss pill from Eli Lilly is hitting the market—and could make one of the fastest-growing drug categories far easier to access. 

Earlier today, the Food and Drug Administration approved orforglipron, marketed as Foundayo, a once-daily pill that works similarly to blockbuster injectable treatments by mimicking hormones that regulate appetite and feelings of fullness. Unlike existing GLP-1 medications that require injections, or strict dosing routines, Foundayo can be taken at any time of day, with or without food or water.

Convenient Pill Poised to Shake Up Market

That convenience could prove to be a major competitive advantage.  “As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world,” David A. Ricks, chair and CEO of Eli Lilly and Company, said in a statement.

Notably, the drug moved through the regulatory process at unusual speed. The FDA reviewed Lilly’s application in under 50 days as part of the Commissioner’s National Priority Voucher pilot program, making it the fastest approval of a new molecular entity in more than two decades, according to CNN. By comparison, most new drug approvals take between six and ten months.

How Anthropic's Claude AI Became a Co-Founder

Foundayo was approved for adults with obesity or those who are overweight with related health conditions, such as high blood pressure, placing it squarely in the same category as widely used GLP-1 treatments like those from Novo Nordisk. But while the science may be similar, the experience is not.

Novo Nordisk’s recently approved oral version of Wegovy, for example, must be taken first thing in the morning at least 30 minutes before food or drink, a restriction that can complicate daily use. Foundayo eliminates that barrier entirely. “We’ve really designed this to fit into people’s lives as easily as possible,” Lilly’s chief scientific officer Dan Skovronsky told CNN.

Even with its dosing constraints, however, Novo’s pill is already estimated to be used by as many as 400,000 people in the U.S., according to CNN, highlighting strong demand for non-injectable options.

© Inc.com